CSPC Innovation Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
CSPC Innovation Pharmaceutical has been growing earnings at an average annual rate of 24.2%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 18% per year. CSPC Innovation Pharmaceutical's return on equity is 13.2%, and it has net margins of 29.5%.
Key information
24.2%
Earnings growth rate
18.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 18.0% |
| Return on equity | 13.2% |
| Net Margin | 29.5% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Estimating The Fair Value Of CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765)
Aug 16
CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) 27% Share Price Plunge Could Signal Some Risk
Jul 04CSPC Innovation Pharmaceutical's (SZSE:300765) Weak Earnings May Only Reveal A Part Of The Whole Picture
Apr 29CSPC Innovation Pharmaceutical (SZSE:300765) Will Pay A Larger Dividend Than Last Year At CN¥0.32
Apr 25CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) P/E Still Appears To Be Reasonable
Apr 24Revenue & Expenses Breakdown
How CSPC Innovation Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 2,129 | 628 | 250 | -1 |
| 31 Mar 24 | 2,307 | 705 | 282 | 16 |
| 31 Dec 23 | 2,502 | 756 | 286 | 47 |
| 30 Sep 23 | 2,670 | 657 | 312 | 330 |
| 30 Jun 23 | 2,729 | 659 | 320 | 332 |
| 31 Mar 23 | 2,804 | 732 | 322 | 179 |
| 01 Jan 23 | 2,626 | 726 | 320 | 46 |
| 30 Sep 22 | 2,694 | 666 | 324 | 42 |
| 30 Jun 22 | 2,384 | 562 | 307 | 33 |
| 31 Mar 22 | 2,034 | 433 | 303 | 32 |
| 01 Jan 22 | 1,850 | 393 | 330 | 27 |
| 30 Sep 21 | 1,333 | 287 | 324 | 18 |
| 30 Jun 21 | 1,338 | 284 | 353 | 16 |
| 31 Mar 21 | 1,319 | 311 | 384 | 14 |
| 31 Dec 20 | 1,317 | 300 | 373 | 14 |
| 30 Sep 20 | 1,329 | 317 | 368 | 12 |
| 30 Jun 20 | 1,290 | 316 | 350 | 13 |
| 31 Mar 20 | 1,270 | 290 | 338 | 13 |
| 31 Dec 19 | 1,257 | 273 | 327 | 13 |
| 30 Sep 19 | 1,299 | 266 | 343 | 13 |
| 30 Jun 19 | 1,277 | 251 | 340 | 12 |
| 31 Mar 19 | 1,281 | 230 | 335 | 12 |
| 31 Dec 18 | 1,240 | 224 | 322 | 11 |
| 30 Sep 18 | 1,149 | 214 | 294 | 12 |
| 30 Jun 18 | 1,111 | 198 | 278 | 14 |
| 31 Mar 18 | 1,064 | 191 | 258 | 11 |
| 31 Dec 17 | 1,031 | 195 | 241 | 9 |
| 31 Dec 16 | 890 | 207 | 162 | 10 |
| 31 Dec 15 | 742 | 116 | 141 | 0 |
| 31 Dec 14 | 651 | 108 | 118 | 0 |
Quality Earnings: 300765 has a high level of non-cash earnings.
Growing Profit Margin: 300765's current net profit margins (29.5%) are higher than last year (24.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300765's earnings have grown significantly by 24.2% per year over the past 5 years.
Accelerating Growth: 300765's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300765 had negative earnings growth (-4.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (0.4%).
Return on Equity
High ROE: 300765's Return on Equity (13.2%) is considered low.